A few years ago, “peptides for weight loss” was a niche bodybuilding-forum search. Now it’s a $50 billion drug category. Ozempic, Wegovy, Mounjaro, and Zepbound are all peptides—and they’ve changed what’s possible with weight loss in a way no diet drug ever has.
But not every peptide marketed for weight loss is the same. There’s a giant gap between FDA-approved injectable medicines and the “peptide therapy” stacks compounded by wellness clinics. Knowing which is which is the entire game.
If peptides as a category are new to you, the peptides overview and what are peptides cover the basics first.
Lose weight
Gain muscles
Eat healthy
Explore new cuisines
Lisa C.
Available on the App StoreThe headliners: GLP-1 receptor agonists
GLP-1 (glucagon-like peptide-1) is a peptide hormone your gut releases after meals. It does three things that matter for weight:
- Tells your pancreas to release insulin
- Slows stomach emptying so you feel full longer
- Signals fullness to your brain
Natural GLP-1 lasts about 2 minutes before enzymes destroy it. Drug companies engineered modified versions that resist breakdown and last for days. The result is a dramatically amplified version of a signal your body already uses.
Semaglutide (Ozempic, Wegovy)
Semaglutide is a once-weekly injection. Ozempic is approved for type 2 diabetes; Wegovy is the same drug at a higher dose, approved for chronic weight management.
The STEP 3 trial enrolled 611 adults with overweight or obesity (without diabetes) for 68 weeks of semaglutide 2.4mg weekly plus intensive behavioral therapy. Average weight loss was 16.0% with semaglutide vs. 5.7% with placebo—about a 10-percentage-point gap.1 86.6% of the semaglutide group lost at least 5% of their starting weight; 55.8% lost at least 15%.
The STEP 4 trial showed something just as important: stop semaglutide and weight comes back. After 20 weeks of treatment producing ~10% weight loss, participants who continued lost another 8%, while those switched to placebo gained back 7%.2 GLP-1 drugs work as long as you take them.
Tirzepatide (Mounjaro, Zepbound)
Tirzepatide hits two receptors—GLP-1 and GIP. The SURMOUNT-1 trial of 2,539 adults with obesity over 72 weeks found:
- 5mg weekly: 15.0% weight loss
- 10mg weekly: 19.5% weight loss
- 15mg weekly: 20.9% weight loss
- Placebo: 3.1%
About 57% of participants on the 15mg dose lost 20% or more of their body weight.3 No oral pill comes close to those numbers.
Liraglutide (Saxenda)
Older once-daily GLP-1. The SCALE trial of 3,731 participants showed an average 8.4 kg loss vs. 2.8 kg on placebo over 56 weeks—much more modest than semaglutide and tirzepatide.4 Mostly displaced now by the weekly injectables.
What to expect on a GLP-1
- Side effects: mostly GI—nausea, diarrhea, constipation, reflux. Worst during dose escalation; usually fade.
- Risks: pancreatitis, gallbladder disease, possible thyroid C-cell tumor risk (boxed warning, derived from rodent data).
- Cost: without insurance coverage, $1,000–$1,400/month brand-name. Compounded versions are cheaper but unregulated (more on that below).
- Muscle loss: about 25% of weight lost on GLP-1s is lean mass. Resistance training and adequate protein matter more here than ever.
- Returning weight: if you stop without lifestyle changes in place, weight tends to come back.
The “research peptides” sold for weight loss
Outside the FDA-approved drugs, a handful of peptides get marketed for fat loss. Most have far weaker evidence.
AOD-9604
A 16-amino-acid fragment of human growth hormone. Promoted as a fat-burner that “works without affecting blood sugar.”
Mouse studies in 2001 showed AOD-9604 reduced body weight and fat in obese mice—but only when β3-adrenergic receptors were intact.5 Human trials over the next two decades have been disappointing. A 12-week trial in adults with obesity found modest but not clinically significant weight loss. Despite that, AOD-9604 is still sold widely through compounding pharmacies and wellness clinics.
Suggested read: Peptides for Muscle Growth: What Works in 2026
Tesofensine
Originally a Parkinson’s drug. Showed strong weight loss in phase 2 trials (10%+) but development stalled over cardiovascular concerns. Currently approved in only a few countries.
“Fat-burning peptide stacks”
Wellness clinics sometimes sell stacks combining CJC-1295, ipamorelin, tesamorelin, or others claiming to boost growth hormone for fat loss. Tesamorelin is FDA-approved for HIV-related lipodystrophy specifically and produces small reductions in visceral fat there. Off-label use for general weight loss in healthy adults isn’t well supported.
For a deeper safety picture of these compounds, see are peptides safe.
Compounded GLP-1s: cheap, but risky
When demand for semaglutide and tirzepatide outpaced supply, the FDA briefly allowed compounding pharmacies to make their own versions. That window has narrowed sharply. Even when allowed:
- Compounded peptides aren’t FDA-reviewed for purity, potency, or sterility
- Reports of dosing errors and contamination have surfaced
- Some products marketed as “semaglutide” turned out to contain different salts or impurities
Before paying out of pocket for compounded versions, check whether your insurance covers a brand-name option, and verify any compounding pharmacy is state-licensed and accredited. The legal landscape is shifting fast—see are peptides legal for current status.
Suggested read: What Is Berberine? Uses, Mechanism, and Evidence
What doesn’t work
Be skeptical of:
- “Oral peptide” weight-loss products. GLP-1 peptides taken by mouth are mostly destroyed by stomach acid. Oral semaglutide (Rybelsus) is a real, FDA-approved version that uses a special absorption enhancer—but it’s far less effective than injection and is approved for diabetes, not obesity.
- “Peptide patches” or sublingual sprays for fat loss. No solid evidence.
- Generic “metabolic peptide” supplements at health food stores. The peptides that actually work for weight loss require a prescription.
What still matters even if you take a peptide
GLP-1 drugs make eating less feel sustainable, but they don’t replace the basics. The trials that produced 15–20% weight loss combined the drug with intensive behavioral therapy—diet counseling, regular check-ins, exercise.
A few things that complement any peptide-based program:
- Protein intake at 1.2–1.6g per kg body weight to limit muscle loss. See how protein helps weight loss.
- Resistance training to preserve lean mass. Best exercises for weight loss covers options.
- Hydration and fiber to reduce constipation and nausea
- Sleep, which has its own effect on appetite hormones
For broader strategy, ways to lose weight naturally covers the lifestyle side.
Who should consider a GLP-1?
Most prescribing guidelines align around:
- BMI ≥30 (obesity), or
- BMI ≥27 with at least one weight-related condition (type 2 diabetes, hypertension, sleep apnea, dyslipidemia)
If you’re at a healthy weight using these for vanity loss, the risk-benefit shifts and most legitimate prescribers won’t write for it.
Bottom line
The peptides that actually move the needle on weight loss are FDA-approved GLP-1 receptor agonists. Semaglutide and tirzepatide produce 15–20% weight loss in 14–18 months when paired with lifestyle changes. They cost a lot, have real side effects, and have to be continued to maintain results.
The rest of the “peptides for weight loss” space—AOD-9604, fat-loss stacks, oral peptide products—is mostly weak evidence and aggressive marketing. Save your money for a doctor who can prescribe a real one or for the basics that work without a needle.
Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413. PubMed ↩︎
Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. PubMed ↩︎
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PubMed ↩︎
Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. PubMed ↩︎
Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-9. PubMed ↩︎
Sarah M.
Linda P.
Maya T.
Marcus J.
Emma R.
Amanda K.
Chris B.
David L.
James W.
Jennifer S.
Kevin H.
Lisa C.
App Store ★★★★★
